Does Ivermectin Interact with Ribociclib?
Yes, ivermectin has a clinically significant drug-drug interaction with ribociclib that requires avoidance of concomitant use.
Mechanism of Interaction
Ivermectin is a strong CYP3A4 inhibitor, and ribociclib is primarily metabolized through the CYP3A4 pathway. According to the FDA label for ribociclib, co-administration with strong CYP3A4 inhibitors substantially increases ribociclib exposure 1.
Specific Pharmacokinetic Impact
When ribociclib is given with ritonavir (a strong CYP3A4 inhibitor like ivermectin), the following increases occur 1:
- Cmax increases by 1.7-fold
- AUC increases by 3.2-fold (more than tripling drug exposure)
In the early breast cancer population receiving ribociclib 400 mg (the dose used with exemestane in your patient), PBPK modeling predicts that strong CYP3A4 inhibitors would increase ribociclib steady-state AUC by 1.84-fold 2.
Clinical Consequences
This magnitude of drug exposure increase significantly raises the risk of:
- QTc prolongation (ribociclib already carries a risk of QT prolongation)
- Grade 3-4 neutropenia (already occurs in 41-59% of patients) 3, 4
- Hepatotoxicity
- Other dose-dependent adverse events
The FDA label explicitly addresses this: for patients requiring a strong CYP3A4 inhibitor, the ribociclib dose must be reduced to 200 mg daily 2. However, this dose reduction is based on modeling and may not fully mitigate the interaction risk.
Clinical Recommendation
Avoid ivermectin entirely in this patient receiving ribociclib plus exemestane for HR+/HER2- breast cancer.
If Ivermectin is Medically Necessary:
- Temporarily hold ribociclib during ivermectin treatment
- Allow adequate washout (at least 5 half-lives of ivermectin, approximately 3-4 days after last dose)
- Resume ribociclib only after ivermectin is cleared
- Consider alternative antiparasitic agents without CYP3A4 inhibition if available
Important Caveats:
- The exemestane component has no clinically relevant interaction with ribociclib 1, so this interaction concern is specific to the ribociclib-ivermectin combination
- Moderate CYP3A4 inhibitors (like erythromycin) show minimal impact on ribociclib 400 mg dosing 2, but ivermectin's strong inhibition exceeds this threshold
- Even with dose reduction to 200 mg, the safety of concurrent strong CYP3A4 inhibitor use has not been prospectively validated in clinical trials
The risk-benefit analysis strongly favors avoiding this combination given the availability of alternative antiparasitic therapies and the critical importance of maintaining optimal ribociclib dosing for breast cancer outcomes 5.